Limerick Plant Production Pause Hits US Pharma Margins
News Context
At a glance
- Regeneron Pharmaceuticals has attributed a decline in its overall group margins to a production pause at its manufacturing facility in Limerick, Ireland.
- The company disclosed a temporary interruption of bulk manufacturing production at its Raheen site in County Limerick, according to reporting by The Irish Independent published April 29, 2026.
- Regeneron identified the cause of the production halt as unanticipated facility repairs.
Regeneron Pharmaceuticals has attributed a decline in its overall group margins to a production pause at its manufacturing facility in Limerick, Ireland.
The company disclosed a temporary interruption of bulk manufacturing production
at its Raheen site in County Limerick, according to reporting by The Irish Independent published April 29, 2026.
Regeneron identified the cause of the production halt as unanticipated facility repairs
.
The details regarding the operational pause and its subsequent impact on the company’s financial margins were included in the organization’s latest quarterly results.